original title:The price of insulin is reduced by 48%. The sixth batch of countries organize the centralized procurement of drugs and produce the results of the proposed selection
The sixth batch of countries organizing the centralized procurement of drugs for insulin was opened in Shanghai on the 26th, and the results of the proposed selection were produced. This centralized procurement covers 16 common name varieties of clinically commonly used second- and third-generation insulins, and the average price of the products to be selected is reduced by 48%.
The purchase demand of medical institutions nationwide for the first year of this centralized procurement is about 210 million. Based on the price before the centralized procurement, the purchase amount involved is about 17 billion yuan. After the centralized procurement, it is expected to save 9 billion yuan each year. Taking the commonly used insulin glargine as an example, from an average of 180 yuan per tube to about 70 yuan per tube, each patient can save about 4,000 yuan per year.
This is the first time that the national organization of centralized drug procurement has expanded to the field of biological drugs, and is an important milestone in the process of centralized procurement reform. Since insulin is an important drug for diabetics to control blood sugar, and patients need to use it for a long time, the centralized procurement of insulin not only promotes the return of insulin prices to a reasonable level and benefits more patients, it is also of great significance for improving the centralized procurement system and achieving the reform goals. .
Based on the successful experience of the early-stage drug and consumable procurement exploration, the National Medical Insurance Administration optimized the procurement rules for the characteristics of insulin, including: First, fully respect the clinical choice, maintain the stability of clinical drug use, and reduce the risk of substitution; Second, the same treatment purpose and The combined competition of different generic names of insulins for clinical action mechanisms takes into account the demand for clinical use and the sufficiency of competition; the third is to attach great importance to the supply of selected products, according to the characteristics of insulin production and use, through investigations on production capacity and reserve sufficient production preparation time, etc. , Take multiple measures to ensure supply.
In this centralized procurement, 11 companies participated in the bidding, and all domestic and foreign companies had their products selected. The products to be selected include both well-known corporate products commonly used by medical institutions and emerging corporate products. While reducing the falsely high prices, they have achieved a high degree of matching with actual clinical needs. (Reporter Peng Yunjia and Gong Wen)
.